Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 7/20 | 0.38 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 7/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27139332 | 1.00 | PTPN11 (0.40) | PTPN11CCR2CCR9SLC40A1TSHR | |
| SCHEMBL30847913 | 0.90 | SLC40A1 (0.38) | PTPN11CCR9SLC40A1 | |
| SCHEMBL27143649 | 0.90 | SLC40A1 (0.38) | PTPN11CCR9SLC40A1 | |
| SCHEMBL27138821 | 0.90 | SLC40A1 (0.38) | PTPN11SLC40A1TSHR | |
| SCHEMBL30848022 | 0.90 | SLC40A1 (0.38) | PTPN11SLC40A1TSHR | |
| SCHEMBL27132412 | 0.84 | SLC40A1 (0.41) | PTPN11CCR9SLC40A1 | |
| SCHEMBL30847917 | 0.84 | SLC40A1 (0.41) | PTPN11CCR9SLC40A1 | |
| SCHEMBL30847889 | 0.84 | SLC40A1 (0.46) | CCR9SLC40A1TSHR | |
| SCHEMBL30847890 | 0.84 | SLC40A1 (0.46) | CCR9SLC40A1TSHR | |
| SCHEMBL27132418 | 0.84 | SLC40A1 (0.46) | CCR9SLC40A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577536-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | Hotspot Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |